Table 2. Baseline Characteristics of the Secondary Prevention Cohort.
| Characteristic | Individuals, No. (%) | ||||
|---|---|---|---|---|---|
| Overall (N = 39 955) | Before weighting | After weighting | |||
| Discontinuation group (n = 9853) | Continuation group (n = 30 102) | Discontinuation group (n = 9855) | Continuation group (n = 30 102) | ||
| Sex | |||||
| Female | 18 717 (46.8) | 5261 (53.4) | 13 456 (44.7) | 4606 (46.7) | 14 098 (46.8) |
| Male | 21 238 (53.2) | 4592 (46.6) | 16 646 (55.3) | 5249 (53.3) | 16 005 (53.2) |
| Age, y | |||||
| Median (IQR) | 80 (77-84) | 81 (78-85) | 80 (77-83) | 80 (77-84) | 80 (77-84) |
| 75-84 | 31 931 (79.9) | 7372 (74.8) | 24 559 (81.6) | 7837 (79.5) | 24 109 (80.1) |
| ≥85 | 8024 (20.1) | 2481 (25.2) | 5543 (18.4) | 2018 (20.5) | 5993 (19.9) |
| Statin intensity | |||||
| Low or moderate | 37 469 (93.8) | 9376 (95.2) | 28 093 (93.3) | 9239 (93.7) | 28 229 (93.8) |
| High | 2486 (6.2) | 477 (4.8) | 2009 (6.7) | 616 (6.3) | 1873 (6.2) |
| Unique medications | |||||
| Median (IQR) | 8 (5-11) | 8 (5-11) | 8 (5-11) | 8 (5-11) | 8 (5-11) |
| 0-4 | 6905 (17.3) | 1855 (18.8) | 5050 (16.8) | 1732 (17.6) | 5162 (17.1) |
| 5-9 | 19 605 (49.1) | 4795 (48.7) | 14 810 (49.2) | 4770 (48.4) | 14 845 (49.3) |
| ≥10 | 13 445 (33.7) | 3203 (32.5) | 10 242 (34.0) | 3354 (34.0) | 10 095 (33.5) |
| Comorbidities | |||||
| Dementia | 4108 (10.3) | 1313 (13.3) | 2795 (9.3) | 1022 (10.4) | 3102 (10.3) |
| Diabetes | 11 702 (29.3) | 2575 (26.1) | 9127 (30.3) | 2900 (29.4) | 8822 (29.3) |
| Atrial fibrillation or flutter | 9079 (22.7) | 2077 (21.1) | 7002 (23.3) | 2267 (23.0) | 6849 (22.8) |
| Heart failure | 8373 (21.0) | 1873 (19.0) | 6500 (21.6) | 2076 (21.1) | 6312 (21.0) |
| Hypertension | 21 903 (54.8) | 5344 (54.2) | 16 559 (55.0) | 5401 (54.8) | 16 500 (54.8) |
| Parkinson | 412 (1.0) | 105 (1.1) | 307 (1.0) | 104 (1.1) | 311 (1.0) |
| COPD | 11 286 (28.2) | 2708 (27.5) | 8578 (28.5) | 2800 (28.4) | 8509 (28.3) |
| Depression | 1551 (3.9) | 405 (4.1) | 1146 (3.8) | 384 (3.9) | 1170 (3.9) |
| Schizophrenia | 16 (0.0) | NR | NR | NR | 12 (0.0) |
| Cancer | 7254 (18.2) | 1738 (17.6) | 5516 (18.3) | 1783 (18.1) | 5465 (18.2) |
| Medications | |||||
| Low dose aspirin | 30 562 (76.5) | 7294 (74.0) | 23 268 (77.3) | 7532 (76.4) | 23 021 (76.5) |
| ADP receptor inhibitors | 3263 (8.2) | 700 (7.1) | 2563 (8.5) | 812 (8.2) | 2460 (8.2) |
| Anticoagulants | 5745 (14.4) | 1241 (12.6) | 4504 (15.0) | 1436 (14.6) | 4332 (14.4) |
| Thiazides | 9160 (22.9) | 2279 (23.1) | 6881 (22.9) | 2247 (22.8) | 6897 (22.9) |
| Spironolactone | 2687 (6.7) | 553 (5.6) | 2134 (7.1) | 658 (6.7) | 2024 (6.7) |
| β blockers | 20 849 (52.2) | 4684 (47.5) | 16 165 (53.7) | 5128 (52.0) | 15 701 (52.2) |
| ACEIs or ARBs | 23 018 (57.6) | 5471 (55.5) | 17 547 (58.3) | 5687 (57.7) | 17 341 (57.6) |
| CCBs | 14 505 (36.3) | 3454 (35.1) | 11 051 (36.7) | 3572 (36.2) | 10 930 (36.3) |
| Antidepressants | 7958 (19.9) | 2001 (20.3) | 5957 (19.8) | 1954 (19.8) | 5992 (19.9) |
| Antipsychotics | 1007 (2.5) | 251 (2.5) | 756 (2.5) | 254 (2.6) | 761 (2.5) |
| NSAIDs (nonselective) | 4697 (11.8) | 1220 (12.4) | 3477 (11.6) | 1154 (11.7) | 3538 (11.8) |
| COX-2 inhibitors | 50 (0.1) | 12 (0.1) | 38 (0.1) | 12 (0.1) | 38 (0.1) |
| Cohabitation status | |||||
| Alone | 19 571 (49.0) | 4483 (45.5) | 15 088 (50.1) | 4836 (49.1) | 14 748 (49.0) |
| Cohabitating | 20 384 (51.0) | 5370 (54.5) | 15 014 (49.9) | 5019 (50.9) | 15 355 (51.0) |
Abbreviations: ACEIs, angiotensin converting enzyme inhibitors; ADP, adenosine diphosphate receptor; ARBs, angiotensin receptor blockers; COPD, chronic obstructive pulmonary disease; CCB, calcium channel blocker; COX-2, cyclooxygenase-2; NR, not reported (numbers were <10); NSAIDs, non-steroidal anti-inflammatory drugs.